FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)
-
-
-
-
-
-
-
Invivyd reports $17.2 million Q4 revenue, up 25% year-over-year
-
-
-
-
-
-
-
Invivyd identifies RSV antibody candidate VBY329 for pediatric prevention
-
-
-
-
-
-
-
Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025
-
-
-
-
-
-
-
Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
-
-
-
-
-
-
-
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
-
-
-
-
-
-
-
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

